We market Actimmune® which is indicated for reducing the frequency and severity of serious infections associated with chronic granulomatous disease (CGD) and for delaying time to disease progression in patients with severe, malignant osteopetrosis.

For additional information on Actimmune® , including full prescribing information, please click on the product link to the right.